Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Impedimed Limited ( (AU:IPD) ) is now available.
ImpediMed Limited held its Annual General Meeting where all proposed resolutions were passed, including the remuneration report and the re-election of board members Ms. Christine Emmanuel-Donnelly and Mr. McGregor Grant. The successful passage of these resolutions indicates strong shareholder support and stability in the company’s governance, which could positively impact its strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, specializing in non-invasive medical devices that measure, monitor, and manage fluid status and body composition. The company focuses on providing solutions for healthcare professionals to improve patient care and outcomes.
Average Trading Volume: 1,744,826
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$79.46M
Learn more about IPD stock on TipRanks’ Stock Analysis page.